

# ASX Release

## SUDA LTD ANNOUNCES NEW ANALYST COVERAGE

**PERTH, AUSTRALIA – 9 February 2016:** SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that Alpha Deal Group, LLC has initiated coverage of SUD. The initiation report, which was commissioned by SUDA, is available on the Company's website via the following link:

<http://www.sudaltd.com.au/index.php/analyst-reports>

Alpha Deal Group is a US-based buy-side advisory and equity intelligence firm focused on identifying uniquely positioned, event-driven, equity growth opportunities for asset managers, hedge funds and private equity firms on several global institutional platforms that include Thomson Reuters Eikon, S&P Capital IQ and FactSet.

The initiation report together with quarterly updates will be distributed to Alpha Deal Group's clients that comprise over 15,000 institutional investors. Alpha Deal Group will also organise road shows in the USA and worldwide for SUDA to have one-to-one meetings with portfolio managers, buy-side analysts and hedge funds.



**Further information:**

**STEPHEN CARTER**

**CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR**

**SUDA LTD**

Tel: +61 8 6142 5555

[sjcarter@sudaltd.com.au](mailto:sjcarter@sudaltd.com.au)

**NOTES TO EDITORS:**

**About SUDA LTD**

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing novel oral spray formulations of existing off-patent pharmaceuticals using its proprietary OroMist® drug delivery technology platform. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist®, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist® has been approved in the USA and SUDA has rights to the product outside of North America. SUDA's most advanced development-stage product, ArTiMist™, is a novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist™ was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction and pre-procedural anxiety. For more information, visit [www.sudaltd.com.au](http://www.sudaltd.com.au)